Calistoga Pharmaceuticals

Calistoga Pharmaceuticals, Inc. is a leader in developing innovative oral drugs that target selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases. The PI3K pathway is a key cellular pathway involved in cell survival and immune cell activation. Calistoga Pharmaceuticals' small-molecule therapeutic candidates inhibit specific isoforms of the PI3K pathway, providing targeted treatment options designed to maximize clinical outcomes while limiting unwanted side effects. Calistoga Pharmaceuticals' lead product, CAL-101, is an oral delta isoform-selective PI3K inhibitor that has demonstrated promising clinical responses in patients with B-cell malignancies and is currently being evaluated in multiple clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals' product development pipeline includes other selective PI3K inhibitors for early preclinical development or preparation for initial clinical trials in patients with cancer or inflammatory diseases.